Other
Northern California Melanoma Center
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
66.7%
-19.8% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT01048554Phase 2Completed
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Role: collaborator
NCT00304200Phase 1Terminated
Temodar and Sutent as Therapy for Melanoma
Role: lead
NCT00350597Phase 2Completed
GM-CSF as Adjuvant Therapy of Melanoma
Role: lead
All 3 trials loaded